Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Booster breakthrough: mRNA shot supercharges immunity in inactivated vaccine recipients

NCT ID NCT05057182

Vaccine Sponsor: The University of Hong Kong Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at 300 adults aged 30 and older who had already received two doses of an inactivated COVID-19 vaccine (like Sinovac or Sinopharm) at least three months earlier. They were given a booster dose of an mRNA vaccine (Pfizer/BioNTech). Researchers measured their antibody levels and checked for side effects to see if the booster safely and effectively increased protection against COVID-19.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

300 people

The number who actually took part.

Started

Oct 2021

Finished

Dec 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

30 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Aged 30 years or older at enrolment. * Have received two doses of any inactivated COVID-19 vaccines (for example Sinovac- CoronaVac, Sinopharm-BIBP) with the most recent dose at least 90 days prior to enrolment. * Currently resident and planning to remain resident in Hong Kong during the duration of the study, i.e. for 12 months after enrolment. * Agreement to refrain from blood donation during the course of the study. * Willing to provide blood samples for all the required time points. * The individual or their caregiver have a home phone or cellular or mobile phone for communications purpose. * Capable of providing informed consent. Exclusion Criteria: * A history of laboratory-confirmed or clinically confirmed COVID-19 infection. Have received (at least one dose of) any COVID-19 vaccines other than inactivated vaccines. * Individuals who report any medical condition, or as determined by a clinician, not suitable to receive mRNA vaccines, including but not limited to allergies to the active substance or other ingredients of the vaccine. * With diagnosed medical conditions related to their immune system. * Use of medication that impairs immune system in the last 6 months, except topical steroids or short-term oral steroids (course lasting ≤ 14 days). * Have used immunoglobulins and/or any blood products within 90 days prior to enrolment (administration of the study vaccine). * Pregnancy, lactation or intention to become pregnant in the coming 3 months.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COVID-19 vaccine are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COVID-19 vaccine

Contacts and locations

Locations

  • The University of Hong Kong

    Hong Kong, 00000, Hong Kong

More trials for these conditions

Other studies related to the condition(s) this trial covers.